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Due to the key role of the lung in efficient transfer of oxygen in exchange for carbon diox-
ide, a controlled inflammatory response is essential for restoration of tissue homeostasis
following airway exposure to bacterial pathogens or environmental toxins. Unregulated
or prolonged inflammatory responses in the lungs can lead to tissue damage, disrupting
normal tissue architecture, and consequently compromising efficient gaseous exchange.
Failure to resolve inflammation underlies the development and/or progression of a num-
ber of inflammatory lung diseases including asthma. Eosinophils, granulocytic cells of the
innate immune system, are primarily involved in defense against parasitic infections. How-
ever, the propagation of the allergic inflammatory response in chronic asthma is thought
to involve excessive recruitment and impaired apoptosis of eosinophils together with
defective phagocytic clearance of apoptotic cells (efferocytosis). In terms of therapeutic
approaches for the treatment of asthma, the widespread use of glucocorticoids is asso-
ciated with a number of adverse health consequences after long-term use, while some
patients suffer from steroid-resistant disease. A new approach for therapeutic intervention
would be to promote the resolution of inflammation via modulation of eosinophil apoptosis
and the phagocytic clearance of apoptotic cells. This review focuses on the mechanisms
underpinning eosinophil-mediated lung damage, currently available treatments and thera-
peutic targets that might in future be harnessed to facilitate inflammation resolution by the
manipulation of cell survival and clearance pathways.
Keywords: eosinophil, lung, inflammation, apoptosis, phagocytosis, allergy, airway, resolution
INTRODUCTION
In response to tissue injury or the presence of micro-organisms,
initiation of host protective mechanisms associated with the acute
inflammatory response can also cause damage to the surrounding
tissue. The release of proteases, glycosidases, and reactive oxy-
gen/nitrogen species can be particularly destructive in the lung,
where disruption of the normal tissue architecture compromises
efficient gaseous exchange. A corollary of this close relationship
between inflammation and tissue injury is that successful res-
olution of inflammation is crucial to optimal restoration and
maintenance of lung function.
The detection of pathogen-associated molecular patterns
(PAMPs) or danger-associated molecular patterns (DAMPs)
via their cognate receptors leads to the production of pro-
inflammatory mediators including tumor necrosis factor-alpha
(TNF-α), interleukin (IL)-1, and IL-6. Well characterized
chemoattractants such as complement fragments (e.g., C3a and
C5a), lipids [e.g., leukotriene B4 (LTB4) and platelet-activating fac-
tor (PAF)], and chemokines [e.g., IL-8 (CXCL8), MCP-1 (CCL2),
and eotaxin (CCL11)] act to recruit and/or activate inflammatory
cells. Together these mediators rapidly perpetuate inflammation
via the activation of vascular endothelial cells, increased vascu-
lar permeability, and edema, concurrent with the recruitment of
granulocytes at the site of injury. In this review, we will discuss the
mechanisms controlling acute lung inflammation, pathological
conditions where the regulation of inflammation has gone awry
and discuss the current and future treatments that could promote
the successful resolution of inflammation.
POLYMORPHONUCLEAR GRANULOCYTES: CRITICAL EFFECTORS OF THE
INNATE IMMUNE RESPONSE
Neutrophils and eosinophils are key immune cells in the host
defense against invading bacteria and parasites. Excessive recruit-
ment, uncontrolled activation, and defective removal of these cells
play a prominent role in the initiation and propagation of a num-
ber of chronic inflammatory conditions (1). Apoptosis, a major
form of programed cell death, is a fundamental process regulating
the tissue longevity of inflammatory cells. Apoptosis provides an
efficient non-inflammatory mechanism for the removal of poten-
tially damaging cells and cellular content from the inflamed site
by resident or recruited monocyte/macrophage populations (2) or
by “non-professional” phagocytes such as epithelial cells (3). The
observation of failed apoptotic cell clearance seen in a number
of chronic inflammatory diseases, including asthma, bronchiecta-
sis, and chronic obstructive pulmonary disease (COPD) provides
strong evidence that granulocyte apoptosis and non-inflammatory
clearance has a key role in the resolution of inflammation.
Neutrophils are continuously generated from pluripotent stem
cells in the bone marrow and are released into the circulation
in large numbers [up to 2× 1011 cells/day (4)]. Once appropri-
ately triggered, circulating neutrophils or those mobilized from
the large marginated pools in the lungs, liver, spleen, and bone
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marrow (5, 6), can be rapidly recruited to the inflammatory site
and engage a number of effector mechanisms to destroy invading
pathogenic organisms. This distinctive machinery includes a com-
bination of reactive oxygen species (ROS) generation, the release
of a cocktail of cytotoxic and proteolytic molecules, phagocyto-
sis, and NETosis (the formation of extracellular chromatin traps)
to destroy invading pathogenic organisms. Recruited neutrophils
can undergo apoptosis which is associated with the “disabling”
of secretion of their potentially harmful granule content thereby
preventing damage to the surrounding tissues (7). The removal
of these apoptotic cells by recruited macrophages or other local
phagocytes, including airway epithelial cells (3), is believed to
facilitate the resolution of inflammation. In addition to apop-
totic cell death, a number of other forms of neutrophil cell death
have been documented, including necrosis, NETosis, autophago-
cytic cell death, necroptosis, oncosis, and pyroptosis [reviewed in
Ref. (8, 9)]. Although the impact of these alternative forms of cell
death on the resolution of inflammatory responses is less clear,
several are believed to be predominantly pro-inflammatory. As
well as local cell death recent studies have provided evidence that
recruited granulocytes can also undergo reverse migration away
from the site of inflammation (10–12), although the consequences
of this on inflammatory processes requires further investigation.
Eosinophils are also derived from granulocytic precursor pop-
ulations in the bone marrow and are readily recruited from res-
idence within hematopoietic and lymphatic organs such as the
lymph nodes, thymus, spleen, and bone marrow (13) via the vascu-
lature to the site of injury in response to parasitic or allergic inflam-
mation (14). Historically, these cells were considered to play little
role in immunoregulation, however, several lines of investigation
have now shown eosinophils to be multifunctional granulocytes
involved in the initiation and propagation of numerous inflam-
matory responses, including modulation of the adaptive immune
response (14). Once at the site of injury, eosinophil degranula-
tion contributes to both the removal of the inflammatory stimuli
and also the propagation of inflammation. Eosinophil-derived
granules contain a wide range of proteins including, major basic
protein, eosinophil cationic protein, eosinophil peroxidase, and
eosinophil-derived neurotoxin, which are known to be cytotoxic
to airway epithelial cells (15, 16). Eosinophils have also been
shown to undergo “traditional” extracellular trap formation (ETo-
sis) termed EETosis (17) as well as facilitating the extracellular
release of mitochondrial chromatin in a ROS-dependent manner
(13). Released mitochondrial DNA and eosinophil-derived gran-
ule proteins combine to form structures, which are capable of
both binding and killing invading organisms in vitro and in vivo
(13), indicating that eosinophils may play a previously unrecog-
nized role in antimicrobial defense. The fate of tissue eosinophils
includes apoptosis (18) and subsequent clearance by phagocytes,
although alternative fates have also been reported.
APOPTOTIC PATHWAYS
There are two major pathways of apoptosis. The intrinsic pathway
is characterized by a conformational change in pro-apoptotic Bcl-2
protein family members, resulting in outer mitochondrial mem-
brane pore formation. The subsequent release of cytochrome c
leads to formation of a complex with apoptotic protease-activating
factor-1 (APAF-1), which then activates the downstream cas-
pases that facilitate apoptosis. In contrast, the extrinsic pathway
is triggered by cell surface death receptor trimerization result-
ing in the activation of Fas-associated protein with death domain
(FADD) and TNF-receptor type 1-associated death domain pro-
tein (TRADD),which is responsible for the autocatalytic activation
of initiator and effector caspases leading to the synchronized
molecular alterations and morphological changes associated with
apoptosis. Thus, the result of these two divergent pathways is
the activation of intracellular caspases (a family of cysteine–
aspartic proteases), which represents a hallmark event in apoptosis
[reviewed in Ref. (8, 19, 20)].
AIRWAY INFLAMMATION
NORMAL LUNG STRUCTURE
The lung is made of up three distinctly different anatomical areas,
the proximal cartilaginous airways, distal bronchioles, and alveoli
(21). The trachea and main bronchi form the proximal cartilagi-
nous airways and are responsible for the conduction of inhaled air,
during which the proximal pseudostratified epithelium provides
defense against invading pathogens and environmental toxins.
In contrast, the epithelium of the distal airways becomes more
columnar and is populated by a large number of ciliated epithelial
cells and mucus-secreting goblet cells (22) – aiding the entrap-
ment and further removal of unwanted inhaled particles (23).
Two types of cells make up the alveolar epithelium; type 1 cells,
which facilitate gaseous exchange, and the type 2 cells produce
numerous secretory vesicles filled with surfactant material, includ-
ing surfactant-associated protein C (24). Thus, in a normal lung
the architectural structure of the tissue works to provide the most
efficient environment for gaseous exchange.
Due to the large surface area and constant barrage of pathogens
and debris found in the air, the lungs have developed efficient
mechanisms for the recognition of microbe-specific motifs. The
respiratory tract is also unique in that it has both an exter-
nal epithelial layer (the respiratory epithelium) and an inter-
nal endothelial layer in close apposition. Therefore, this unique
structure could provide difficulties when attempting to pharma-
cologically target the tissue resident eosinophils rather than the
airway-resident cells.
NEUTROPHIL-DOMINANT AIRWAY INFLAMMATION
In tissue localized infection, the exposure of neutrophils to bac-
terial products or endogenous mediators leads to “priming” of
function and facilitates chemotaxis toward the site of infection or
injury. Up regulation of surface adhesion molecules (P-selectin,
ICAM1, and VCAM1) on the vascular endothelial cells that inter-
act with adhesion molecules on the neutrophil is required for
the tethering, rolling, intravascular crawling, and transmigration
of activated neutrophils from the circulation into the tissue to
carry out their effector functions [reviewed in Ref. (4)]. Develop-
ment and progression of two neutrophil-driven airway diseases;
COPD, characterized by impaired airflow to the lungs as a result
of an abnormal inflammatory response (25), and bronchiectasis, a
chronic debilitating respiratory disease, characterized by a“vicious
cycle” of permanently dilated airways, increased mucus produc-
tion, and recurrent infections (26), have been linked to failed
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resolution of inflammation (27–29). However, despite persistent
neutrophil-driven inflammation, reduced bacterial clearance is
also seen (30). Thus, failure to clear bacterial pathogens from the
airways leads to a prolonged inflammatory response character-
izing the vicious cycle of inflammation and infection described,
with both neutrophil and bacterial derived products contributing
to damage of the surrounding epithelial cells.
Currently prescribed treatments for COPD and bronchiecta-
sis include β2-adrenergic receptor agonists (e.g., salmeterol and
formoterol), anticholinergic therapies (e.g., tiotropium bromide),
high dose inhaled glucocorticoids, theophylline and treatments
to improve mucociliary clearance, and sputum expectoration.
These drugs work to reduce symptoms, improve lung func-
tion, and exercise capacity in an attempt to return to normal
health status (26, 31–34). Furthermore, as well as traditional
anti-inflammatory effects including inhibition of ROS release,
decreased adhesion to the vascular endothelium and reduced
release of pro-inflammatory cytokines from macrophages (35),
salmeterol has also been shown to reduce adherence of bacteria
to airway epithelial cells (36, 37), demonstrating that it may be
effective at treating both the underlying infections and resultant
inflammatory response.
EOSINOPHIL DOMINANT AIRWAY INFLAMMATION
Eosinophil dominant allergic inflammation is characterized by
three distinct phases (Figure 1). On initial exposure of the air-
way to an allergen, the sensitization stage, allergens are taken up
by dendritic cells either within the airway lumen or in the sub-
mucosa after penetrating the epithelial barrier. The antigens are
then presented to naïve T cells, which differentiate and activate
local B cells to produce IgE. Secreted IgE then binds to Fcε recep-
tors on the surface of submucosal tissue resident mast cells, thus
priming the immune system. On second exposure to the allergen,
surface bound IgE becomes cross-linked leading to the activation
of the tissue resident mast cells. Inflammatory mediators are then
released and initiate the propagation of inflammation character-
ized as the second phase of allergic inflammation, the early-phase
reaction. Release of histamine, LTB4, TNF-α, IL-8, IL-13, CCL2,
and VEGFA from mast cells leads to increased vascular endothe-
lial permeability, promoting the recruitment and transmigration
of granulocytes from the circulation into the tissue. IL-13, hista-
mine and TNF-α also act directly on the goblet cells found within
the airway epithelium, causing increased mucus production.
Transendothelial migration of eosinophils to the inflamed site
marks the progression into the third stage of the inflammatory
response – the late-phase reaction. This usually develops 6–9 h
after allergen exposure. Continued secretion of eosinophil recruit-
ing cytokines (e.g., GM-CSF, IL-5, and IL-3) by mast cells leads to
the prolonged eosinophil infiltration, representing a major con-
tributory factor to the initiation and maintenance of eosinophilic
airway inflammation in asthma (19, 38) – key cytokines involved
in eosinophil recruitment are summarized in Table 1. Subsequent
eosinophil degranulation and release of intracellular cytotoxic
contents such as eosinophil basic protein results in damage to air-
way epithelial cells with increased mucus production from goblet
cells and airway bronchoconstriction as a result of IL-13 secretion
lead to reduced airflow, airway damage, goblet cell hyperplasia, and
Table 1 | Key cytokines involved in eosinophil recruitment.
KEY CYTOKINES
Eotaxin-1 (CLL11) (47, 48)
GM-CSF (49)
Interleukin-5 (IL-5) (49)
Interleukin-3 (IL-3) (38, 49)
MCP-3 (48)
Eotaxin-2 (CCL24) (47)
RANTES (CCL5) (48–50)
MIP-1α (CCL3) (48, 50)
disrupted tissue architecture and remodeling. Mast cell production
of IL-8 and TNFα also triggers the recruitment of neutrophils and
elastase release causing further tissue degradation.
Continuous exposure to allergens leads to persistent, chronic
inflammation, which is associated with changes in tissue architec-
ture and cell composition and extensive tissue remodeling. In par-
ticular, patients with chronic asthma develop increased goblet cell
hyperplasia. Persistent residence of eosinophils and neutrophils
within the submucosa results in the continuous production of
pro-inflammatory cytokines, lack of inflammatory resolution, and
a repetitive cycle of tissue injury and inflammation (Figure 1).
The most characteristic features of eosinophil dominant aller-
gic asthma is bronchial inflammation leading to non-specific
airway hyperreactivity (39), mucus plugging of airways, epithelial
cells loss, mucus gland hyperplasia, epithelial basement membrane
thickening, edema of the submucosa, smooth muscle hypertrophy,
and inflammatory cell infiltration (40). In vitro studies have shown
that eosinophil granule-derived proteins are partly responsible for
the damage seen in asthma as eosinophil cationic protein and
major basic protein are both cytotoxic to the bronchial epithelium
(16) and have been shown to affect ciliary beat and function (41)
and increase non-specific bronchial hyperreactivity (42), all of
which are classical pathological findings of asthma (40). Interest-
ingly, a number of studies using eosinophil-deficient mice (PHIL)
have shown that eosinophils enhance airway mucus accumula-
tion and hyperresponsiveness, collagen deposition, and smooth
muscle hypertrophy (43, 44). However, a significantly increased
mucus index was still observed in ovalbumin treated PHIL mice
(43) suggesting that although eosinophils contribute substantially
to airway remodeling, they are not obligatory for allergen-induced
injury (44), indicating activation of both eosinophil-dependent
and -independent mechanisms of injury after airway allergen
challenge (43).
Current treatments for asthma include inhalable bron-
chodilators (β2-adrenergic agonists and anticholinergic drugs),
leukotriene receptor antagonists, glucocorticoids, and theo-
phylline (45, 46). The possible mechanisms of actions for these
drugs are shown in Table 2.
Mast cells are known to play an important role in the prop-
agation and pathogenesis of allergen-induced inflammatory dis-
ease (51, 52), due to their involvement in the sensitization stage,
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FIGURE 1 | Allergen driven allergic inflammation: progression from the
sensitization phase, to early and late inflammatory phase. Airway
exposure results in the allergen being taken up by submucosal dendritic cells.
Antigen presentation to B cells, via T cell–dendritic cell interactions, leads to
IgE release – marking the sensitization phase. IgE binding to Fcε receptors on
the tissue resident mast cells leads to allergen-induced IgE receptor
crosslinking and mast cell degranulation – marking the early-phase of the
inflammatory response. The release of of LTB4, TNF-α, IL-8, IL-13, CCL2, and
VEGFA from mast cells results in eosinophil recruitment, increased vascular
permeability, and increased mucus secretion by goblet cells. Continued
exposure to the allergen, and infiltration of granulocytes to the inflamed
tissue marks the progression to the late phase of the inflammatory response.
Prolonged secretion of IL-13 and the release of intracellular cytotoxic granules
by recruited eosinophils (and neutrophils) lead to continual tissue damage,
mucus hypersecretion, and tissue remodeling resulting in the gradual loss of
normal lung function.
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Table 2 | Mechanisms of action of agents currently used for routine
treatment of allergic airways disease.
Mediator/drug Biological response Reference
Glucocorticoids Alter pro- and anti-inflammatory
cytokine balance
(55, 56)
Enhances phagocytic capacity of
macrophages and airway epithelial
cells
(57–59)
Promotes eosinophil apoptosis
in vitro possibly via reduction of
Mcl-1 levels
(1, 60)
β2-Adrenergic
receptor agonists
(e.g., salmeterol
and formoterol)
Highly selective bronchodilator
Reduce adherence of bacteria to
airway epithelial cells
(61–63)
(36, 37)
Anticholinergic drugs
(e.g., tiotropium
bromide)
Effective bronchodilators (32)
Leukotriene receptor
antagonists
Prevent leukotriene induced
bronchoconstriction, mucus
hyper secretion, and airway
inflammation
(64)
Increase eosinophil apoptosis
in vitro
(65)
Theophylline Bronchodilator (66, 67)
Accelerates eosinophil apoptosis
in vitro possibly by suppressing
anti-apoptotic protein Bcl-2 levels
(68, 69)
Reduced airway eosinophilia and
ECP levels in vivo
(70)
Figure 1. As these tissue resident cells are long lived and can
survive repeated activation, the modulation of their prolifera-
tion and survival has been proposed as a potential therapeutic
intervention for allergic disease (53). Recently, Wechsler et al.
showed that thymol, a monocyclic phenolic plant compound
with known antiseptic, antibiotic, antifungal, and antioxidant
properties, was able to induce mast cell apoptosis in vitro and
in vivo (54), thereby highlighting a potential pathway for modu-
lating the allergic response through the manipulation of mast cell
viability.
FAILINGS IN CURRENT TREATMENTS: WHY NEW
APPROACHES ARE NEEDED?
New approaches for the management of inflammatory airway dis-
eases are urgently needed as current treatments are associated with
a number of adverse health consequences after long-term use.
For example, the management of allergic asthma is largely based
around preventing exposure of the sensitized individuals to the
allergen and treating with therapies which are directed toward
alleviating and/or treating the symptoms of the disorder, such as
inhaled glucocorticoids. However, this often poses a problem as a
small subpopulation of asthma sufferers, often those with “neu-
trophilic”asthma, are noted to be steroid resistant (71), resulting in
increased disease severity (72). Equally the undesirable side effects
that arise from long-term use of glucocorticoids (the most com-
mon treatment prescribed for eosinophil dominant inflammatory
conditions) include osteoporosis, hypertension, muscle atrophy,
and delayed wound healing, all of which place limitations on use
of glucocorticoid-based anti-inflammatory therapies.
REGULATION OF GRANULOCYTE APOPTOSIS
As the resolution of inflammation likely depends on the apopto-
sis and phagocytosis of apoptotic granulocytes, research into the
pharmacological manipulation of these processes is increasingly
being recognized as an important area of research for the devel-
opment of novel strategies to enhance the resolution of chronic
inflammation (27, 73–76) and improve patient health.
The rates of granulocyte apoptosis are amenable to alteration
by exogenous pharmacological compounds. Both the rates of neu-
trophil and eosinophil apoptosis can be accelerated by treatment
with, soluble Fas ligand (Fas-L) (77), gliotoxin (78), and cyclin-
dependent kinase inhibitors (CDKi) (73, 74, 79). Neutrophil
apoptosis can also be delayed by pro-inflammatory cytokines
(e.g., TNF-α and IL-1) (78), bacterial products [e.g., lipopolysac-
charide (LPS), lipoteichoic acid, and peptidoglycan] (80, 81),
growth factors [e.g., granulocyte macrophage-colony stimulat-
ing factor (GM-CSF)] (75), and pharmacological agents including
dibutyryl-cAMP (82, 83) and glucocorticoids (1, 84). TNF-α has
been reported to have both pro- and anti-apoptotic effects on
neutrophils, with early apoptosis and late survival seen during
exposure of cultured cells. It is thought that at early time points
(2–8 h) during in vitro culture a subpopulation of neutrophils
undergo caspase-8 dependent apoptosis, with later survival (16–
24 h) dependent upon an NF-κB mediated anti-apoptotic signal-
ing pathway. Similarly, NF-κB inhibition in eosinophils allows
TNF-α mediated apoptosis to predominate (85).
One important difference between the two granulocyte pop-
ulations is that in vitro treatment of human granulocytes with
glucocorticoids promotes eosinophil apoptosis, whereas it delays
neutrophil apoptosis (5). It is also important to note that the
survival effect of glucocorticoids on neutrophil longevity may be
dependent on the environmental milieu (86, 87). Marwick et al.
demonstrated in vitro that the pro-survival effects of glucocorti-
coids on neutrophils are dependent on oxygen levels, with severe
hypoxia (1% oxygen) attenuating glucocorticoid-mediated neu-
trophil survival (87). This observation has important implications
for the therapeutic efficacy of glucocorticoids when prescribed
for neutrophil-dominant inflammatory conditions, due to the
relatively high oxygen concentrations found in the lung.
One way that glucocorticoids are thought to mediate their anti-
inflammatory effects is through the expression and function of
the downstream effector molecule Annexin A1 (AnxA1) (86, 88).
AnxA1 has been shown to promote human neutrophil apopto-
sis via dephosphorylation of the Bcl-2-antagonist of cell death
(BAD) promoting cell death via the intrinsic pathway of apopto-
sis (89). In vitro investigations showed that endogenous AnxA1
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was released by apoptotic neutrophils and glucocorticoid-treated
macrophages, which then acts in both a para- and autocrine man-
ner to promote the phagocytic clearance of apoptotic neutrophils
(90, 91). Increased production of AnxA1 by innate immune
cells following glucocorticoid administration reportedly leads to
decreased neutrophil endothelial transmigration, increased neu-
trophil apoptosis and increased phagocytosis of apoptotic cells
by macrophages (88, 92). This mechanism was further sup-
ported by in vivo experiments in which administration of an
anti-AnxA1 antibody prevented glucocorticoid-induced resolu-
tion of inflammation, whereas treatment with AnxA1-derived
peptides promoted the resolution of inflammation (86). Further
work is required to define the role of AnxA1 in the resolution of
eosinophilic inflammation.
A number of classically“pro-inflammatory”eosinophil recruit-
ing cytokines, IL-25 (93), IL-33 (94), IL-3, IL-5,and thymic stromal
lymphopoietin (TSLP) (95) have also been shown to delay the rate
of eosinophil apoptosis (96). Due to their key role in the recruit-
ment and activation and of eosinophils in inflammatory sites, there
is interest in developing anti-cytokine therapies, such as anti-IL-5
antibodies [reviewed in Ref. (97)], as potential therapeutic targets.
Historically, there has been a number of disappointing results sur-
rounding anti-IL-5 treatments in humans, potentially as a result
of the unique architecture of the lungs localizing their effect to the
airway resident, rather than the tissue resident, eosinophils.
NOVEL REGULATORS OF EOSINOPHIL APOPTOSIS
The regulation of cell apoptosis by pro- and anti-apoptotic Bcl-2
family members has been well documented (20). However,as gran-
ulocytes have a limited number of mitochondria (98), it was some-
what surprising when members of this protein family were found
to modulate the regulation of granulocyte apoptosis. Eosinophils
were found to express high levels of pro-apoptotic Bax molecules,
and were also found to express a number of anti-apoptotic mem-
bers of the Bcl-2 family (99). Mcl-1, an important anti-apoptotic
protein in neutrophils (27), is also thought to play a predominant
role in eosinophils, as previous work reported that Mcl-1 lev-
els decreased in glucocorticoid-treated eosinophils, whereas they
remained at a constant level in glucocorticoid-treated neutrophils
(60), which may go some way to explain their differential effect on
the two granulocyte populations.
Since granulocytes are considered to be terminally differenti-
ated cells, the central role of active cyclin-dependent kinases (key
regulators of the cell cycle) in the control of apoptosis was surpris-
ing. The structurally distinct CDKis R-roscovitine and AT7519
promoted apoptosis in a caspase-dependent manner (73, 76) by
the down-regulation of intracellular Mcl-1 levels in vivo (79, 100,
101) and prevented GM-CSF-mediated up regulation of Mcl-1
(73). R-roscovitine was also shown to have pro-resolving effects
in vivo in a number of models of inflammation (73) while AT7519
increased the percentage of apoptotic eosinophils as well as the
percentage of macrophages containing apoptotic eosinophils in
a mouse model of allergic pleurisy, indicating that AT7519 has
the potential to resolve allergic inflammation by driving both
eosinophil apoptosis and by increasing macrophage clearance of
apoptotic cells (76). Evidence suggests that these CDKIs target
CDK7 and CDK9, which are involved in transcription of key
granulocyte survival proteins such as Mcl-1 (102). Further studies
investigating the mechanisms underlying resolution of inflam-
mation have also highlighted the importance of Mcl-1 in the
regulation of granulocyte apoptosis. Flavones, polyphenolic plant-
derived compounds, rapidly induced both eosinophil (103) and
neutrophil apoptosis (101) in vitro even in the presence of pow-
erful pro-survival mediators including LTA, GM-CSF (101), and
IL-5 (103).
Another powerful driver of caspase induced eosinophil apopto-
sis is antibody crosslinking of sialic acid binding immunoglobulin-
like lectin 8 (Siglec-8), a member of the Siglec immunoglobu-
lin supergene family expressed only on the surface of human
eosinophils, basophils, and mast cells (104). Siglec-8 cross-
linking reduced eosinophil viability in a time- and concentration-
dependent manner through the induction of caspase-mediated
apoptosis. This was further confirmed by the use of pan (104)
and selective caspase inhibitors (against caspase-8 and -9) (105),
which completely inhibited Siglec-8 cross-linking induced apopto-
sis in vitro, while having no effect on spontaneous eosinophil apop-
tosis. Antibody crosslinking of the functional mouse ortholog,
Siglec-F, was also shown to significantly reduce peripheral
eosinophil number in a hypereosinophilic/chronic eosinophilic
leukemic (HES/CEL) murine model, as well as induce eosinophil
apoptosis in vivo (106). These data further highlight that regu-
lation of eosinophil apoptosis using exogenous mediators could
provide potential future therapeutic targets for eosinophilic
disorders.
Pharmacological modulation of endogenous molecules
involved in mediating the resolution of allergic inflammation is
also a key area of research. Recently, Faustino et al. showed that
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
is a major player in the resolution process, with in vivo administra-
tion of anti-TRAIL markedly reducing the number of apoptotic
cells in the BAL fluid of chronic allergy induced mice (107).
In vivo, treatment with recombinant TRAIL, in an established
mouse model of allergic airway inflammation, also significantly
augmented the number of apoptotic cells found in the BAL of
OVA treated mice, compared to control (PBS treated mice), as
well as decreasing the overall number of eosinophils found in the
BAL (107), providing further evidence that the manipulation of
eosinophil apoptosis may provide avenues for the discovery of
novel therapeutics.
LIPID MODULATION
Lipoxins, protectins, and resolvins are bioactive lipids synthe-
sized from arachidonic, docosahexaenoic, and eicosapentaenoic
acid, respectively (108, 109). They are key pro-resolution media-
tors, which act to selectively prevent granulocyte migration and
increase the recruitment of phagocytic cells (110). Both lipoxin
A4 and B4 were reported to inhibit neutrophil recruitment to
an inflammatory site and lipoxin A4 was also shown to stim-
ulate monocyte chemotaxis and promote macrophage uptake
of apoptotic neutrophils in vitro (111, 112) and in vivo (113).
Similar inhibitory effects of lipoxin A4 upon the migration
and chemotaxis of eosinophils in vivo and the local generation
of eotaxin and IL-5 have been reported (114, 115). Resolvins
also have pro-resolution effects preventing transepithelial and
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transendothelial migration of neutrophils in vivo (116), and
stimulating the non-inflammatory phagocytosis of apoptotic
neutrophils (117).
The significance of pro-resolving lipids in successful resolution
of inflammation has also been noted in a number of non-allergic
and allergic inflammatory conditions. Reduced levels of protectin
D1 and lipoxin A4 are seen in the exhaled breath of patients after
a severe and mild asthma exacerbation, respectively (118, 119).
In vivo, mouse models have also provided insight into the role of
pro-resolving lipids in the recruitment of granulocytes and aug-
mentation of macrophage phagocytic capacity – resolvin E1 and
lipoxin analogs were shown to reduce airway hyperresponsiveness
(119), eosinophil number (118), and promote inflammation res-
olution in a mouse model of allergic asthma (119, 120). Given the
pro-resolution roles of these lipid mediators, there is great inter-
est in the development of them as therapeutics. However, as these
endogenously produced molecules are traditionally locally active
and rapidly inactivated the development of exogenously admin-
istered drugs with longer half-lives, which mimic endogenous
compounds in vivo are needed to fill this pharmacological niche.
Currently, the synthetic resolvin analog RX-10045, and naturally
occurring small molecule lipid mediator RX-10001 and are under
clinical examination for their use in a number of inflammatory
diseases such as dry eye, asthma, retinal disease, and inflammatory
bowel disease (109).
MANIPULATION OF PHAGOCYTOSIS
One newly emerging approach to facilitate the resolution of
inflammation is the pharmacological manipulation of the phago-
cytosis of apoptotic granulocytes (121). As well as their effects
on granulocyte apoptosis, glucocorticoids are also known to aug-
ment macrophage phagocytic function (57), which may represent
an approach to drive clearance of apoptotic cells from inflamed
sites (122). Glucocorticoid-treated macrophages exhibit altered
cytoskeletal regulation, with increased cell motility and expression
of high levels of active Rac, a key protein involved in cell motility,
mitosis, wound healing, and phagocytosis (123).
Glucocorticoids induce phagocytosis of apoptotic cells via Mer,
a member of the Tyro-3/Axl/Mer (TAM) receptor tyrosine kinase
family (58, 124, 125). TAMs are widely expressed vertebrate-
specific receptor tyrosine kinases that confer the capacity for bind-
ing and subsequent phagocytosis of apoptotic cells, together with
initiation of signals that regulate cellular function. TAM-deficient
mice show defective clearance of apoptotic material by retinal pig-
ment epithelial cells of the eye, Sertoli cells of the testis and also
by myeloid cells. Interestingly, a number of autoimmune condi-
tions are associated with impaired or failed clearance of apoptotic
cells (126) and the absence of TAM receptors results in progres-
sive loss of vision, reduced fertility, and development of overt
autoimmunity (122, 127, 128). Recent studies demonstrate that
Mer-mediated apoptotic cell clearance has a critical importance
pathophysiologically in the lung, as inflammation in an LPS-
induced lung injury model was amplified following Mer blockade
(129), and conversely attenuated following up regulation of Mer-
signaling by use of TAPI-0 (a specific inhibitor of Mer cleavage)
(130). The expression of Mer on phagocytic populations present
at the inflammatory site could also be induced by treatment with
glucocorticoids (57) or liver X receptor agonists (131). Alterna-
tively, blockade of cytokines that actively suppress Mer expression
(e.g., interferon-gamma) could represent an alternative strategy
for promoting Mer-dependent apoptotic cell clearance (132, 133).
Recent evidence suggests that Mer is down regulated by inflamma-
tory stimuli such as LPS or bleomycin via proteolytic cleavage from
the phagocyte membrane (134). Specific inhibition of ADAM17
proteolytic activity (e.g., using KD-1X-73.5 or TAPI-0) prevents
Mer down-regulation and is associated with increased clearance of
apoptotic cells in both LPS and bleomycin models of lung injury
(135), providing a potential therapeutic approach to increase Mer-
dependent clearance mechanisms in inflammation. Definition of
the molecular mechanisms of phagocyte–apoptotic cell interac-
tions and regulation by glucocorticoids will provide opportunities
to identify novel targets for therapeutic gain.
EPITHELIAL CELL PHAGOCYTOSIS
In addition to the importance of therapies, which are able to mod-
ulate apoptotic cell phagocytic clearance, identification of the cell
types which carry out this process in inflammatory airway condi-
tions is of crucial importance. Induced death of airway epithelial
cells as a result of exposure to environmental toxins, allergens,
and pathogens has been observed and documented in patients
with asthma (3). Thus, there is a need for a large population
of local airway phagocytic cells to remove the apoptotic debris.
There is mounting evidence that a number of “non-professional”
phagocytes, including mammary epithelial (136) and microvascu-
lar endothelial cells (137) are also able to phagocytose apoptotic
cells. Work published by Walsh et al. and Sexton et al. showed that
bronchial epithelial cells are capable of recognizing and engulf-
ing apoptotic eosinophils, suggesting a non-passive role of the
airway epithelium in the resolution of eosinophilic inflammation
in asthma (138, 139). More recently, Juncadella et al. showed that
bronchial epithelial cells are also critically involved in the phagocy-
tosis of apoptotic airway epithelial cells, which subsequently alters
the production of anti-inflammatory cytokines and control of air-
way hyperresponsiveness in a murine model of allergic airway
inflammation (3). Despite the potential for providing novel ther-
apeutic approaches for the treatment of inflammatory diseases,
little work has been done to investigate the potential for manipu-
lation of the phagocytic ability of these cells in current models of
inflammatory airway diseases.
SUMMARY
In conclusion, recent research into the pharmacological manipula-
tion of apoptosis and efferocytosis of apoptotic cells has provided
novel insights into the treatment of inflammatory airway dis-
eases, notably eosinophil dominant airway inflammation. This
dual approach will open up new areas for therapeutic intervention,
allowing the successful manipulation of inflammation resolution,
as well as reducing the adverse effects associated with currently
available treatments.
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